Focus: QED Therapeutics is a Palo Alto-based biotech company specializing in small-molecule tyrosine kinase receptor inhibitors targeting rare diseases, oncology, and metabolic conditions. The company is actively hiring (96 open roles) and advancing a portfolio anchored by infigratinib across multiple indications.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Contracting — net -26 jobs in 30d
28 added, 54 removed. Active reduction in progress.
Best suited for biotech professionals seeking growth-stage exposure with meaningful pipeline depth, but regulatory and execution risk remains until Phase 3 data matures.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for QED Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from QED Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles